Table 2: Review of response outcomes with ILI.
| Author | Year | n | Complete response rate (n) | Partial response rate (n) | Minimal response rate (n) | Overall response rate (n) | Limb salvage rate (n) | Grade IV/V toxicity | Chemo agent(s) (n) |
| Hegazy MA, et al. [1]* | 2007 | 40 | n/a | 30% (12) | 55% (22) | 85% (34) | 98% (39) | 0% | DOX (40) |
Moncrieff MD, et al. [2] |
2008 |
21 |
57% (12) |
33% (7) |
n/a |
90% (19) |
76% (16) |
14% (3) |
L-PAM (16) MMC/L-PAM (3) L-PAM/DACT (1) MMC/DOX/CDDP (1) |
| Turaga KK, et al. [21] | 2011 | 12 | 17% (2) | 58% (7) | n/a | 75% (9) | 78% (11) | 0% | DACT/L-PAM (12) |
| Vohra NN, et al. [3] | 2013 | 17 | 24% (4) | 18% (3) | n/a | 42% (7) | 71% (12) | 0% | DACT/L-PAM (17) |
| Wong J, et al. [22] | 2013 | 20 | 15% (3) | 45% (9) | n/a | 60% (12) | n/a | 0% | DACT/L-PAM (21) |
*ILI used in combination with external beam radiotherapy.
DOX: Doxorubicin; MMC: Mitomycin-C; L-PAM: Melphalan; DACT: Dactinomycin; CDDP: Cisplatin; n/a: not applicable.